Engflag

Aramine

Quick links to important sections

Aramine

Aramine_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aramine

Aramine (Metaraminol): Identity and Classification

Property Description
Active Ingredient Metaraminol (bitartrate salt)
Form Solution for Injection
Pharmacological Class Sympathomimetic Amine / Vasopressor
General Use Acute Circulatory Support
Origin Synthetic

Aramine is the trade name for the pharmaceutical drug whose active ingredient is Metaraminol, a potent agent specifically formulated for the circulatory system. This substance is chemically classified as a sympathomimetic amine and, functionally, as a vasopressor. It is a synthetic derivative, meaning the compound is produced through chemical synthesis rather than being naturally sourced. The drug's classification as a vasopressor indicates its main purpose: to rapidly increase blood pressure.

Composition and General Benefit

Metaraminol is supplied as a sterile solution for injection, a formulation that ensures its swift entry into the bloodstream for immediate effect. The final medication is composed of the Metaraminol active ingredient dissolved in an aqueous base (Water for Injection). In the United States, Metaraminol is typically formulated as the bitartrate salt in a concentration equivalent to 10 mg/mL of the base. This formulation confirms that the drug is designed solely for parenteral delivery, which is required for immediate pressor effect.

The general purpose of Aramine is to provide acute circulatory support and rapidly elevate blood pressure in urgent, life-threatening scenarios. Metaraminol is classified as an agent used for the treatment of hypotension. The clinical benefit is the prompt restoration of perfusion pressure to vital organs, such as the brain and kidneys, preventing cellular damage and sustaining essential organ function during periods of acute hypotension.

What side effects are possible with Aramine?

Official Safety Profile of Aramine (Metaraminol Bitartrate)

The safety profile of Aramine is dominated by its powerful effects on the cardiovascular and nervous systems, as documented in official government regulatory labels.

Serious Adverse Reactions

The most serious documented reactions include life-threatening severe hypertension (excessively high blood pressure) and ventricular arrhythmias (serious irregular heart rhythms), including ventricular fibrillation. Profound bradycardia (extremely slow heart rate) is also a documented serious risk. A hazard exists at the injection site, where tissue necrosis (death of tissue) or sloughing may occur if the drug leaks outside the vein (extravasation).

System-Organ Classes of Adverse Reactions

Adverse reactions that are commonly reported or associated with the drug's use involve several body systems:

  • Heart and Blood Vessels: Hypertension, palpitation, bradycardia, and other arrhythmias.
  • Nervous System: Tremor, dizziness, headache, and apprehension.
  • Digestive System: Nausea and vomiting.
  • General: Flushing and sweating.

Safety-Related Restrictions and Limitations

Certain conditions and drug combinations are subject to strict regulatory warnings or contraindications (situations where the drug should not be used):

  • Anesthetics: Use is generally prohibited with cyclopropane or halogenated hydrocarbon anesthetics (e.g., halothane, isoflurane) due to the heightened risk of serious ventricular arrhythmias.
  • MAO Inhibitors: Use with or within 14 days of discontinuing monoamine oxidase (MAO) inhibitors is severely restricted, as it can precipitate a dangerous, prolonged hypertensive crisis.
  • Pre-existing Conditions: Caution is required in individuals with hypertension, thyrotoxicosis, or diabetes mellitus.

Population-Specific Safety

  • Pregnancy: Regulatory documents warn that the drug may cause fetal harm, specifically severe fetal bradycardia and death when administered near term.
  • Pediatrics: Safety and effectiveness for use in children have not been established.

Exposure-Related Pattern

Regulatory sources note that the effect of Aramine in raising blood pressure may diminish with prolonged or repeated use (tachyphylaxis).

Overdose and Emergency Response

Overdosage with Aramine (Metaraminol), a potent vasopressor, is formally documented to result primarily from an excessive elevation of blood pressure, a condition that requires immediate medical attention. Clinical manifestations noted in regulatory documents include severe hypertension, headache, a constricting sensation in the chest, nausea, vomiting, euphoria, and diaphoresis. Overdose can also result in serious cardiovascular signs, such as tachycardia, bradycardia, or other atrial or ventricular arrhythmias.

The official overdose profile emphasizes the risk of life-threatening outcomes, including myocardial infarction, cardiac arrest, pulmonary oedema, and convulsions. If an excessive blood pressure elevation occurs, the intravenous infusion must be stopped immediately. Management involves counteracting the hypertensive effects, often with a sympatholytic agent such as phentolamine, and administering an appropriate antiarrhythmic agent if rhythm disturbances arise. Supportive measures described for managing exposure include gastric lavage if the drug was ingested. The regulatory labeling notes a specific risk of fatal ventricular arrhythmia in patients with Laenne’s cirrhosis under excessive vasopressor effect.

Therapeutic Uses of Aramine

Aramine (Metaraminol) is a medication applied in clinical settings that involve acute or unstable symptom patterns related to systemic imbalance, where supportive management may be appropriate. This medication is primarily relevant for conditions associated with acute or disruptive episodes of profound low blood pressure and vascular instability.

The medication is commonly used to help manage severe symptomatic hypotension, including when symptoms present as various forms of shock, such as septic, cardiogenic, or hemorrhagic. It helps address symptom clusters that may become intense or disruptive by providing immediate support, and may be used to help address critically low systemic pressure. This supportive action plays a role in supporting the patient in urgent scenarios.

Furthermore, Aramine is relevant for easing the symptomatic consequence of inadequate blood flow (poor perfusion), particularly in critical settings like the perioperative environment. Its uses include managing acute hypotension following spinal anesthesia, treating hypotension resulting from hemorrhage, and addressing drops in pressure due to reactions to medications. This provides supportive relief by supporting the restoration of perfusion pressure, which helps patients cope more steadily with symptom fluctuations during these critical episodes.

“Applied in contexts involving heightened systemic burden, it assists with maintaining functional stability.”

Quick Fact: Relief for Profound Low Blood Pressure This agent is generally used only for immediate, short-term support when blood pressure symptoms present as a critical, sudden threat to functional stability.

Regulatory References

  1. New Zealand Medsafe Product Datasheet

Eligibility and Restrictions for Use

Who Can and Cannot Use Aramine?

Aramine (Metaraminol) is reserved for use in adult patients requiring acute circulatory support for severe hypotension, provided no absolute prohibitions exist. Official regulatory documents define eligibility constraints across key domains, distinguishing between absolute prohibitions and restrictions requiring caution.

Absolute Contraindications (Cannot Use)

Use is strictly prohibited for patients with:

  • Known hypersensitivity to Metaraminol or any component in the formulation, including sulfites (sodium metabisulfite).
  • Hypotension caused by uncorrected hypovolemia (low blood volume).
  • Concurrent use with cyclopropane or halothane anesthesia.

Conditional Use (Use with Caution)

Caution is officially mandated for patients with specific, pre-existing conditions, including:

  • Heart disease (due to arrhythmia risk), hypertension, thyroid disease, or diabetes mellitus.
  • Cirrhosis, requiring particular caution and adequate electrolyte restoration.
  • A history of malaria.

Age and Special Populations

The drug is not recommended for children under 12 years as its safety and effectiveness have not been established in this age group. Geriatric patients may exhibit increased sensitivity, requiring particular caution. For pregnant women, use is restricted (Category C in the US) and only permitted when the potential benefit clearly justifies the potential risk. Caution is advised during breastfeeding as it is unknown if the medicine passes into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metaraminol's interaction profile, documented in official regulatory sources, centers on pharmacodynamic reinforcement and metabolic restrictions.

Contraindicated Combinations and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This restriction is due to a metabolic interaction where MAOIs inhibit the clearance of Aramine, resulting in severe potentiation and prolongation of the pressor effect. A mandatory separation period (often 14 days) must be observed following the discontinuation of irreversible MAOIs. Use is also restricted with inhaled General Anesthetics like Cyclopropane or Halothane because of a documented risk of inducing cardiac arrhythmias.

Pharmacodynamic and Exposure Effects

Official documents note that Oxytocic Drugs (e.g., Oxytocin) may cause severe, persistent hypertension when co-administered. The vasopressor action is also potentiated by Tricyclic Antidepressants and other Sympathomimetic Agents. Combining Aramine with Digitalis Glycosides is documented to increase the likelihood of ectopic arrhythmic activity. Conversely, the pressor effect is officially decreased by co-administration with Alpha-Adrenergic Blocking Agents. Regulatory information cautions that a cumulative effect is possible after prolonged use, risking an excessive vasopressor response.

Mechanism of Action

Dual Action on Alpha-1 Adrenergic Receptors

Aramine (Metaraminol) acts as a sympathomimetic amine by two primary, concurrent mechanisms: it directly stimulates Alpha-1 (alpha1) Adrenergic Receptors on peripheral blood vessels, and it acts indirectly by releasing the body’s own signaling molecule, norepinephrine, from storage sites in nerve terminals. This dual engagement enhances adrenergic signaling, which initiates the Gq cascade in the vessel walls.

Modulation of Peripheral Vascular Tone

The activation of alpha1 receptors triggers an increase in the internal calcium concentration within vascular smooth muscle cells, causing these muscles to contract. This contraction leads directly to widespread vasoconstriction, increasing the Systemic Vascular Resistance (SVR). This physiological change is the mechanism responsible for the resulting elevation of arterial pressure.

Mechanism Dependence and Tachyphylaxis

The mechanism has a known constraint: the indirect action relies entirely on the availability of endogenous norepinephrine stores. The indirect action’s reliance on NE stores can result in tachyphylaxis (a progressively weaker effect) when the substrate becomes depleted. Conversely, the molecule’s resistance to natural metabolic breakdown enzymes (MAO and COMT) accounts for its prolonged activity relative to native catecholamines.

Dosage and Administration Information

Official Administration Guidelines

Aramine (metaraminol) is supplied only as a Solution for Injection (10 mg/mL) and must be administered strictly via a parenteral route. Administration methods and standard adult dosages are defined based on the drug's formulation and clinical application.

Administration Method Standard Dosing Regimen Use Context
Intravenous (IV) Infusion 15 to 100 mg in 500 mL of diluent. Rate is continuously adjusted (titrated) to maintain the required systemic pressure. Primary method for continuous support.
Direct IV Injection (Bolus) 0.5 to 5 mg (0.05 to 0.5 mL of 10 mg/mL solution). Reserved for grave emergencies when prompt action is imperative.
Intramuscular (IM) / Subcutaneous (SC) 2 to 10 mg (0.2 to 1 mL). Used for prevention or less severe hypotension in some regions.

Procedural and Timing Rules

For IV infusion, the concentrated solution must be diluted using approved solutions like Sodium Chloride Injection or 5% Dextrose Injection. Since the maximum effect is not immediately apparent, the practice is to allow at least ten minutes to elapse before increasing the dosage. The drug is for acute, short-term management only, and the infusion rate must be gradually decreased when therapy is discontinued; abrupt withdrawal can result in acute drops in blood pressure. The larger veins of the antecubital fossa or thigh are the preferred injection sites to minimize local risks.

Population Considerations

The safety and efficacy of metaraminol in children under 12 years of age have not been established, restricting its use in this population. While geriatric dosage may not require modification, older adults may be more sensitive to the drug's effects, requiring cautious use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aramine (Metaraminol)

Evidence for Acute Hypotension in Anesthesia

Research examined the use of Aramine in studies focusing on episodes of low blood pressure (hypotension) that may occur following spinal or epidural anesthesia, particularly during surgical procedures like Cesarean delivery. This area of study was evaluated in various randomized controlled trials (RCTs) and systematic reviews, where research explored whether Metaraminol contributes to maintaining blood pressure stability during the procedure.

These studies monitored physiological strain, specifically recording outcomes related to systemic imbalance, such as the maternal blood pressure (measuring the incidence of hypotension and hypertension). The studies also monitored outcomes linked to fetal well-being, including the acid-base balance and newborn Apgar scores. Findings describe patterns observed in the studies related to measured changes in blood pressure levels.

It is important to note that the results apply only to the populations studied, which were largely low-risk pregnant adults. This suggests that data for certain groups remain limited, and long-term effects are not fully established for either the mother or the infant beyond the immediate postnatal period due to limited follow-up durations.

Evidence for Hemodynamic Support and Research Gaps

Aramine was evaluated in settings involving critically ill adults with conditions characterized by acute or disruptive episodes of very low blood pressure (shock). This research base relies more heavily on observational studies and older, smaller controlled trials. Studies monitored various outcomes reflecting systemic or functional imbalance, including changes in mean arterial pressure (MAP) and hospital survival rates. Observational research reported rapidly measured changes showing a rise in systemic blood pressure in the observed populations.

The certainty remains low in this area. A major research gap is the lack of current, large-scale, high-quality randomized controlled trials comparing Metaraminol with modern first-line vasopressors for general, severe shock management. Scientific reviews suggest the comparative evidence is lacking when evaluating Metaraminol against other standard agents. Evidence quality varies across studies, and long-term effects are not fully established because follow-up durations were limited.

Key Studies & References

  1. Aramine Injection 10 mg/mL (Metaraminol bitartrate) - New Zealand Medsafe Datasheet

Frequently Asked Questions (FAQ)

Common questions about Aramine (FAQ)

Q: What is the main reason doctors prescribe Aramine?

A: Aramine is primarily indicated for the prevention and treatment of acute hypotensive states—meaning sudden, severe episodes of low blood pressure. Official regulatory documents list its use in situations that may arise due to spinal anesthesia, hemorrhage, or certain complications during surgery or shock. The drug's documented purpose is to rapidly elevate blood pressure to support vital circulation.

Q: How quickly does Aramine start to work after it is given?

A: The time it takes for Aramine to begin its effect depends on how it is administered. According to official product information, the pressor effect starts within 1 to 2 minutes when given through an IV (intravenous) line. Following an intramuscular injection, an effect is typically seen within about 10 minutes.

Q: How long do the effects of Aramine usually last?

A: The blood pressure-raising effect of Aramine is described as relatively short-acting. Official clinical pharmacology information indicates that the effects of a dose typically last from about 20 minutes up to one hour.

Q: Why do official documents say Aramine should only be used in a hospital setting?

A: Official documents describe Aramine as being used to manage acute or grave emergencies involving low blood pressure. Due to its powerful effects, the drug requires careful observation, which often means continuous monitoring of blood pressure and heart function. This level of supervision points to the drug's use being restricted to a controlled clinical environment, such as a hospital.

Q: What kind of monitoring is needed when a patient is receiving Aramine?

A: Because Aramine is a potent vasopressor, its administration requires close oversight. Official guidelines often mention the need for continuous monitoring of blood pressure and cardiac activity (heart rate and rhythm). The injection site is also frequently checked for any signs of extravasation (leakage outside the vein).

Q: Do people ever become dependent on Aramine?

A: Official regulatory information, such as the Consumer Medicine Information (CMI) leaflets, states that there is no evidence that Aramine is addictive or causes dependence.

Q: Are there different brand names for the drug metaraminol?

A: Yes, Metaraminol is the active ingredient in the medicine. While the brand name Aramine is used in certain regions, the same active ingredient may be sold under different brand names or as a generic product in various countries. The official product labeling identifies the medicine by its active ingredient, Metaraminol.

Q: Does Aramine change how other drugs are processed by the body?

A: Yes, official drug interaction information notes that Aramine can interact with how other medicines work. For example, it can potentiate (strengthen) the effects of certain antidepressants and other sympathomimetic agents. Regulatory information emphasizes the need for medical staff to be aware of all medications to assess potential interactions.

Q: Is Aramine ever used to treat fainting spells?

A: Official indications specify that Aramine is for the treatment of acute hypotensive states (severe, sudden drops in blood pressure) in a clinical setting. It is not indicated or documented for the general treatment of chronic or non-specific fainting spells, also known as syncope.

Q: What common foods or drinks are known to interact with Aramine?

A: The official documentation primarily focuses on interactions with other medications and does not list extensive food or drink restrictions. However, information indicates that products high in stimulants, such as caffeine, may enhance effects on blood pressure and heart rate.

Q: Can patients travel while receiving treatment with Aramine?

A: Aramine is administered in a hospital setting for the management of acute hypotension and requires continuous medical monitoring. Therefore, receiving treatment with Aramine is not consistent with traveling. The official instructions define the drug as being used only in supervised clinical environments.

Q: Is Aramine a type of adrenaline?

A: No, Aramine is not the same as adrenaline (epinephrine). According to clinical pharmacology, it is classified as a sympathomimetic amine that primarily acts by releasing stored norepinephrine and stimulating alpha1 adrenergic receptors, which is a different mechanism from Adrenaline (Epinephrine).

Q: Should I tell my doctor about all the supplements I take before getting Aramine?

A: Regulatory documents emphasize the importance of medical staff being aware of all medicines, including herbal products or supplements, so they can assess any potential for interaction.

Q: Can Aramine cause issues with blood flow to the fingers or toes?

A: Official regulatory documents list reduced blood supply to the arms and legs as a possible side effect of the drug. Since Aramine works by causing widespread vasoconstriction (narrowing of blood vessels), this effect is documented to potentially affect the circulation in the extremities, including the hands and feet.

Q: What is the maximum amount of time someone can be on Aramine?

A: Official documentation states that Aramine is for acute, short-term management of low blood pressure. While no specific universal time limit is set, clinical guidelines suggest that the duration of infusion should generally be limited and is closely monitored by medical staff.

Q: Does having kidney problems affect how Aramine is used?

A: Official precautions advise caution for patients with certain pre-existing conditions, including liver disease such as cirrhosis, where careful management of fluid balance is needed. Although not specifically listed, any condition affecting the organs responsible for clearance, such as kidney problems, generally requires heightened caution during use.

Q: Is Aramine the same type of drug as norepinephrine?

A: No. Aramine is a sympathomimetic amine that works by causing the release of the body’s own norepinephrine from nerve endings, in addition to direct receptor stimulation. Norepinephrine itself is a naturally occurring catecholamine, while Aramine is a synthetic compound.

Q: What should a patient expect to feel as Aramine starts to work?

A: Aramine is administered to address low blood pressure, and patients may experience an alleviation of symptoms related to poor circulation. However, patients may also experience some documented side effects, such as headache, tremor, dizziness, or palpitations, as listed in the official safety profile.

Q: Is Aramine ever used outside of the operating room or intensive care?

A: Aramine's use is documented for managing acute hypotension often encountered during surgery or in critical care settings. However, surveys and guidelines in some regions indicate it may also be used in emergency departments or for medical emergencies that arise on general hospital wards.

Q: Why is the drug given by slow injection or infusion?

A: Official warnings state the administration technique is used to avoid rapid changes in blood pressure. This is a safety measure, as excessively fast rises in blood pressure can potentially lead to serious side effects like pulmonary edema (fluid in the lungs) or cardiac arrhythmias (irregular heartbeats).

How should Aramine be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Aramine (Metaraminol Injection) are strictly defined by regulatory documents to ensure product stability and environmental safety.

Storage Conditions:

Requirement Specifics
Temperature Store at or below 25 C (controlled room temperature).
Protection Keep ampoules in the outer carton to protect from light. Do not freeze.
Child Safety Keep this medicine out of the sight and reach of children.

Handling and Stability:

The product is for single use only. Any unused portion of the solution must be immediately discarded. If the product is diluted for administration in a sterile environment, its stability is limited to a short, specified period (e.g., 24 to 48 hours) when stored under refrigeration (2 C to 8 C). The solution must be checked for particles before use.

Disposal:

Official instructions require that unused or expired Aramine not be disposed of via household trash or poured into wastewater. Medicines must be returned to a pharmacy or designated collection system to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aramine found in:

A-Z Index: